Hillary Lum
Concepts (452)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Advance Care Planning | 48 | 2026 | 242 | 15.820 |
Why?
| | Dementia | 10 | 2026 | 302 | 3.920 |
Why?
| | Patient Portals | 8 | 2025 | 49 | 3.880 |
Why?
| | Palliative Care | 23 | 2026 | 996 | 3.680 |
Why?
| | Caregivers | 17 | 2026 | 1047 | 2.880 |
Why?
| | Advance Directives | 10 | 2025 | 87 | 2.400 |
Why?
| | Primary Health Care | 17 | 2026 | 1710 | 2.250 |
Why?
| | Patient Participation | 6 | 2024 | 429 | 1.990 |
Why?
| | Aged | 76 | 2026 | 25850 | 1.990 |
Why?
| | Hospice Care | 5 | 2023 | 217 | 1.740 |
Why?
| | Skilled Nursing Facilities | 8 | 2026 | 151 | 1.710 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 451 | 1.700 |
Why?
| | Physicians | 9 | 2024 | 938 | 1.680 |
Why?
| | Suicide, Assisted | 6 | 2024 | 31 | 1.670 |
Why?
| | Terminal Care | 6 | 2023 | 279 | 1.650 |
Why?
| | Aged, 80 and over | 33 | 2026 | 8243 | 1.620 |
Why?
| | Communication | 15 | 2024 | 961 | 1.520 |
Why?
| | Physician-Patient Relations | 9 | 2024 | 581 | 1.490 |
Why?
| | Huntington Disease | 2 | 2024 | 61 | 1.470 |
Why?
| | Electronic Health Records | 8 | 2025 | 1169 | 1.440 |
Why?
| | Humans | 140 | 2026 | 144261 | 1.340 |
Why?
| | Parkinson Disease | 4 | 2026 | 600 | 1.290 |
Why?
| | Pandemics | 8 | 2025 | 1682 | 1.280 |
Why?
| | Documentation | 5 | 2024 | 197 | 1.240 |
Why?
| | Qualitative Research | 18 | 2026 | 1659 | 1.210 |
Why?
| | Surveys and Questionnaires | 22 | 2026 | 6021 | 1.150 |
Why?
| | Volunteers | 2 | 2019 | 39 | 1.130 |
Why?
| | Subacute Care | 5 | 2024 | 82 | 1.130 |
Why?
| | Hospices | 2 | 2022 | 89 | 1.100 |
Why?
| | Home Care Services | 6 | 2025 | 280 | 1.080 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1519 | 1.060 |
Why?
| | Social Isolation | 2 | 2025 | 72 | 1.060 |
Why?
| | Authorship | 2 | 2026 | 49 | 1.050 |
Why?
| | Loneliness | 2 | 2025 | 59 | 1.050 |
Why?
| | Male | 70 | 2026 | 72035 | 1.040 |
Why?
| | Heart Failure | 7 | 2023 | 2314 | 1.030 |
Why?
| | Emergency Service, Hospital | 5 | 2026 | 2301 | 1.030 |
Why?
| | Female | 74 | 2026 | 77976 | 1.010 |
Why?
| | Quality Improvement | 6 | 2023 | 1285 | 1.000 |
Why?
| | Accidental Falls | 2 | 2025 | 222 | 0.930 |
Why?
| | Adult Children | 1 | 2025 | 26 | 0.900 |
Why?
| | Middle Aged | 35 | 2026 | 35762 | 0.870 |
Why?
| | Object Attachment | 1 | 2025 | 48 | 0.860 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2025 | 1409 | 0.840 |
Why?
| | Patient Care Team | 5 | 2025 | 686 | 0.830 |
Why?
| | Home Health Aides | 1 | 2023 | 6 | 0.820 |
Why?
| | Medical Marijuana | 3 | 2020 | 123 | 0.790 |
Why?
| | Mass Screening | 4 | 2026 | 1332 | 0.790 |
Why?
| | Ambulatory Care Facilities | 3 | 2026 | 264 | 0.760 |
Why?
| | Life Support Care | 2 | 2020 | 40 | 0.760 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 107 | 0.750 |
Why?
| | Group Processes | 2 | 2020 | 64 | 0.750 |
Why?
| | Medicare | 5 | 2024 | 881 | 0.740 |
Why?
| | Health Services for the Aged | 2 | 2020 | 70 | 0.740 |
Why?
| | Parent-Child Relations | 1 | 2025 | 270 | 0.730 |
Why?
| | Feasibility Studies | 4 | 2026 | 1087 | 0.710 |
Why?
| | Nursing Homes | 5 | 2026 | 172 | 0.710 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 340 | 0.710 |
Why?
| | Interviews as Topic | 7 | 2026 | 898 | 0.680 |
Why?
| | Living Wills | 1 | 2020 | 8 | 0.670 |
Why?
| | Housing | 1 | 2022 | 144 | 0.660 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1347 | 0.660 |
Why?
| | Music Therapy | 1 | 2020 | 22 | 0.650 |
Why?
| | Outpatients | 2 | 2024 | 439 | 0.650 |
Why?
| | Patient-Centered Care | 3 | 2021 | 540 | 0.650 |
Why?
| | Music | 1 | 2020 | 47 | 0.630 |
Why?
| | Alzheimer Disease | 2 | 2025 | 619 | 0.620 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 706 | 0.610 |
Why?
| | Inservice Training | 2 | 2017 | 116 | 0.600 |
Why?
| | Virtual Reality | 1 | 2020 | 76 | 0.590 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 150 | 0.580 |
Why?
| | Sports | 1 | 2021 | 211 | 0.580 |
Why?
| | Pharmacists | 1 | 2021 | 240 | 0.580 |
Why?
| | CD40 Antigens | 4 | 2006 | 90 | 0.560 |
Why?
| | Resuscitation Orders | 4 | 2024 | 47 | 0.560 |
Why?
| | Internship and Residency | 2 | 2021 | 1255 | 0.560 |
Why?
| | Stakeholder Participation | 1 | 2019 | 83 | 0.560 |
Why?
| | Attitude of Health Personnel | 7 | 2024 | 1182 | 0.550 |
Why?
| | Activities of Daily Living | 1 | 2022 | 440 | 0.550 |
Why?
| | Independent Living | 2 | 2018 | 114 | 0.550 |
Why?
| | Patient Discharge | 6 | 2026 | 977 | 0.550 |
Why?
| | Geriatric Assessment | 2 | 2024 | 231 | 0.530 |
Why?
| | Long-Term Care | 3 | 2024 | 117 | 0.520 |
Why?
| | Health Services Accessibility | 3 | 2026 | 1091 | 0.520 |
Why?
| | Hospitalization | 5 | 2023 | 2424 | 0.520 |
Why?
| | Betacoronavirus | 1 | 2020 | 285 | 0.520 |
Why?
| | Physicians, Primary Care | 1 | 2019 | 206 | 0.510 |
Why?
| | Geriatrics | 3 | 2024 | 96 | 0.490 |
Why?
| | United States | 17 | 2026 | 15876 | 0.490 |
Why?
| | Clinical Protocols | 1 | 2018 | 282 | 0.490 |
Why?
| | Perception | 2 | 2020 | 377 | 0.480 |
Why?
| | Parents | 1 | 2025 | 1401 | 0.480 |
Why?
| | Social Media | 1 | 2019 | 171 | 0.480 |
Why?
| | Pilot Projects | 9 | 2026 | 1867 | 0.470 |
Why?
| | Nurse Practitioners | 1 | 2018 | 139 | 0.470 |
Why?
| | Marijuana Use | 4 | 2020 | 213 | 0.460 |
Why?
| | Patient Education as Topic | 5 | 2019 | 777 | 0.460 |
Why?
| | Policy | 1 | 2016 | 146 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 382 | 0.450 |
Why?
| | Patient Care Planning | 4 | 2026 | 169 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 377 | 0.450 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 95 | 0.440 |
Why?
| | Drug Utilization | 1 | 2015 | 166 | 0.430 |
Why?
| | Life Change Events | 1 | 2015 | 144 | 0.420 |
Why?
| | Decision Making | 5 | 2026 | 974 | 0.420 |
Why?
| | Adult | 17 | 2026 | 40262 | 0.400 |
Why?
| | Education, Medical | 1 | 2017 | 273 | 0.400 |
Why?
| | Physician's Role | 1 | 2015 | 218 | 0.400 |
Why?
| | Patient Readmission | 4 | 2021 | 756 | 0.400 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 336 | 0.390 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5813 | 0.380 |
Why?
| | Nurses | 1 | 2015 | 178 | 0.370 |
Why?
| | Quality of Life | 4 | 2026 | 3166 | 0.340 |
Why?
| | Endothelium, Vascular | 6 | 2011 | 963 | 0.340 |
Why?
| | Canada | 5 | 2023 | 428 | 0.340 |
Why?
| | Culture | 1 | 2012 | 125 | 0.340 |
Why?
| | Melanoma, Experimental | 3 | 2006 | 108 | 0.340 |
Why?
| | Patient Navigation | 2 | 2025 | 104 | 0.340 |
Why?
| | Patient Selection | 2 | 2025 | 719 | 0.340 |
Why?
| | Interpersonal Relations | 1 | 2014 | 399 | 0.330 |
Why?
| | Emergency Medical Services | 1 | 2018 | 696 | 0.330 |
Why?
| | Patients | 1 | 2012 | 178 | 0.320 |
Why?
| | Health Status | 1 | 2016 | 833 | 0.320 |
Why?
| | Health Information Exchange | 2 | 2021 | 24 | 0.320 |
Why?
| | Retrospective Studies | 8 | 2026 | 17009 | 0.320 |
Why?
| | Age Factors | 4 | 2025 | 3313 | 0.320 |
Why?
| | Depression | 3 | 2018 | 1533 | 0.310 |
Why?
| | Telemedicine | 4 | 2025 | 940 | 0.310 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1318 | 0.300 |
Why?
| | Cardiac Surgical Procedures | 2 | 2025 | 609 | 0.300 |
Why?
| | Electronic Mail | 2 | 2019 | 61 | 0.290 |
Why?
| | Health Communication | 2 | 2019 | 54 | 0.270 |
Why?
| | Influenza, Human | 1 | 2014 | 615 | 0.270 |
Why?
| | Referral and Consultation | 5 | 2025 | 847 | 0.270 |
Why?
| | Neoplasms | 4 | 2026 | 2870 | 0.270 |
Why?
| | Peer Group | 2 | 2020 | 242 | 0.260 |
Why?
| | Neuroblastoma | 2 | 2006 | 174 | 0.260 |
Why?
| | Hospital Mortality | 1 | 2012 | 1027 | 0.260 |
Why?
| | Organizations, Nonprofit | 1 | 2007 | 17 | 0.260 |
Why?
| | Colorado | 9 | 2024 | 4562 | 0.260 |
Why?
| | Social Work | 3 | 2024 | 85 | 0.250 |
Why?
| | Clinical Decision-Making | 2 | 2022 | 358 | 0.240 |
Why?
| | Emergence Delirium | 1 | 2025 | 7 | 0.240 |
Why?
| | Health Resources | 1 | 2007 | 129 | 0.230 |
Why?
| | Peer Review, Research | 1 | 2026 | 36 | 0.230 |
Why?
| | Automobile Driving | 2 | 2019 | 155 | 0.230 |
Why?
| | Grounded Theory | 1 | 2025 | 46 | 0.220 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 240 | 0.220 |
Why?
| | Immunotherapy | 2 | 2008 | 652 | 0.220 |
Why?
| | Immunization, Passive | 1 | 2005 | 87 | 0.220 |
Why?
| | Empathy | 2 | 2025 | 181 | 0.210 |
Why?
| | Telerehabilitation | 1 | 2025 | 43 | 0.210 |
Why?
| | Delirium | 1 | 2025 | 104 | 0.210 |
Why?
| | Multimorbidity | 1 | 2025 | 61 | 0.210 |
Why?
| | Antibodies, Bispecific | 1 | 2005 | 64 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 402 | 0.200 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2134 | 0.200 |
Why?
| | Neurology | 1 | 2025 | 110 | 0.200 |
Why?
| | Oncologists | 1 | 2024 | 46 | 0.200 |
Why?
| | Elder Abuse | 1 | 2024 | 50 | 0.200 |
Why?
| | Internet | 2 | 2018 | 698 | 0.200 |
Why?
| | Periodicals as Topic | 1 | 2026 | 203 | 0.200 |
Why?
| | Self Concept | 1 | 2025 | 252 | 0.190 |
Why?
| | T-Lymphocytes | 4 | 2006 | 1982 | 0.190 |
Why?
| | Anesthesiology | 1 | 2026 | 175 | 0.190 |
Why?
| | Sleep Aids, Pharmaceutical | 1 | 2022 | 4 | 0.190 |
Why?
| | Delphi Technique | 3 | 2026 | 329 | 0.190 |
Why?
| | Healthcare Disparities | 2 | 2021 | 725 | 0.190 |
Why?
| | Information Dissemination | 1 | 2024 | 220 | 0.180 |
Why?
| | Language | 1 | 2025 | 321 | 0.180 |
Why?
| | Interleukin-2 | 3 | 2009 | 437 | 0.180 |
Why?
| | Thrombin | 3 | 1998 | 165 | 0.180 |
Why?
| | Video Recording | 2 | 2025 | 211 | 0.180 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 16 | 0.170 |
Why?
| | Death | 1 | 2022 | 130 | 0.170 |
Why?
| | Macrophages, Peritoneal | 3 | 2006 | 89 | 0.170 |
Why?
| | Digital Divide | 1 | 2021 | 3 | 0.170 |
Why?
| | Family | 1 | 2026 | 679 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1217 | 0.170 |
Why?
| | Nitric Oxide | 1 | 2006 | 897 | 0.170 |
Why?
| | Macrophages | 2 | 2006 | 1510 | 0.170 |
Why?
| | Recovery of Function | 1 | 2025 | 706 | 0.170 |
Why?
| | HIV-1 | 1 | 2007 | 895 | 0.170 |
Why?
| | Comorbidity | 2 | 2016 | 1646 | 0.170 |
Why?
| | Deprescriptions | 1 | 2021 | 34 | 0.160 |
Why?
| | Personhood | 1 | 2020 | 5 | 0.160 |
Why?
| | Hearing Loss | 1 | 2024 | 247 | 0.160 |
Why?
| | Geriatric Psychiatry | 1 | 2020 | 11 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1050 | 0.160 |
Why?
| | Macrophage Activation | 3 | 2006 | 193 | 0.160 |
Why?
| | Program Evaluation | 1 | 2025 | 946 | 0.160 |
Why?
| | Multiple Chronic Conditions | 1 | 2020 | 34 | 0.160 |
Why?
| | Perioperative Care | 1 | 2022 | 230 | 0.160 |
Why?
| | Receptors, GABA-A | 1 | 2021 | 138 | 0.160 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1129 | 0.160 |
Why?
| | Organization and Administration | 1 | 2019 | 14 | 0.150 |
Why?
| | Health Expenditures | 1 | 2021 | 194 | 0.150 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 194 | 0.150 |
Why?
| | Communication Barriers | 2 | 2025 | 124 | 0.150 |
Why?
| | Health Plan Implementation | 1 | 2020 | 136 | 0.150 |
Why?
| | Europe | 1 | 2020 | 412 | 0.150 |
Why?
| | Reimbursement Mechanisms | 1 | 2019 | 79 | 0.150 |
Why?
| | Patient Preference | 2 | 2022 | 221 | 0.150 |
Why?
| | Alcoholism | 1 | 2026 | 808 | 0.150 |
Why?
| | Health Personnel | 1 | 2025 | 742 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1705 | 0.140 |
Why?
| | Software Design | 1 | 2018 | 25 | 0.140 |
Why?
| | Veterans | 2 | 2025 | 1600 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 27 | 0.140 |
Why?
| | Medical Futility | 1 | 2018 | 31 | 0.140 |
Why?
| | Community-Institutional Relations | 1 | 2019 | 101 | 0.140 |
Why?
| | Inpatients | 1 | 2023 | 542 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 37 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2001 | 250 | 0.140 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 4278 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2006 | 223 | 0.140 |
Why?
| | Capillary Permeability | 1 | 1998 | 134 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 297 | 0.130 |
Why?
| | Needs Assessment | 1 | 2020 | 401 | 0.130 |
Why?
| | Isoenzymes | 1 | 1998 | 299 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2005 | 974 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 163 | 0.130 |
Why?
| | Clinical Competence | 1 | 2025 | 1241 | 0.130 |
Why?
| | Research Personnel | 1 | 2019 | 183 | 0.130 |
Why?
| | Ecosystem | 1 | 2022 | 589 | 0.130 |
Why?
| | Reading | 1 | 2018 | 136 | 0.130 |
Why?
| | Cognition | 1 | 2025 | 1258 | 0.130 |
Why?
| | Protein Kinase C | 1 | 1998 | 252 | 0.130 |
Why?
| | Program Development | 1 | 2019 | 369 | 0.120 |
Why?
| | Rural Population | 1 | 2022 | 648 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2022 | 688 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 394 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2926 | 0.120 |
Why?
| | Universities | 1 | 2019 | 451 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2019 | 545 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2020 | 358 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2025 | 2916 | 0.120 |
Why?
| | Neoplasms, Experimental | 2 | 2008 | 173 | 0.120 |
Why?
| | Community Health Services | 1 | 2018 | 232 | 0.120 |
Why?
| | Hypesthesia | 1 | 2016 | 21 | 0.120 |
Why?
| | Cannabis | 2 | 2020 | 509 | 0.120 |
Why?
| | Housing for the Elderly | 1 | 2015 | 7 | 0.120 |
Why?
| | Disease Management | 2 | 2019 | 643 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 729 | 0.110 |
Why?
| | Financing, Personal | 1 | 2015 | 27 | 0.110 |
Why?
| | Chest Pain | 1 | 2016 | 98 | 0.110 |
Why?
| | Pain Management | 1 | 2019 | 405 | 0.110 |
Why?
| | Calcium | 2 | 1998 | 1182 | 0.110 |
Why?
| | Professional Role | 1 | 2016 | 158 | 0.110 |
Why?
| | Workflow | 1 | 2016 | 184 | 0.110 |
Why?
| | Prospective Studies | 4 | 2025 | 7970 | 0.110 |
Why?
| | Environment | 1 | 2016 | 305 | 0.110 |
Why?
| | Terminology as Topic | 1 | 2017 | 255 | 0.110 |
Why?
| | Young Adult | 3 | 2021 | 13990 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 403 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2001 | 1339 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1057 | 0.100 |
Why?
| | Firearms | 1 | 2020 | 435 | 0.100 |
Why?
| | Cytokines | 4 | 2006 | 2061 | 0.100 |
Why?
| | Cell Line, Tumor | 6 | 2009 | 3539 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 919 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2016 | 376 | 0.100 |
Why?
| | Motivational Interviewing | 1 | 2015 | 116 | 0.100 |
Why?
| | State Medicine | 1 | 2012 | 27 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1533 | 0.090 |
Why?
| | Signal Transduction | 3 | 2001 | 5221 | 0.090 |
Why?
| | HIV Infections | 1 | 2007 | 3079 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 878 | 0.090 |
Why?
| | Risk Factors | 4 | 2025 | 10699 | 0.090 |
Why?
| | Attitude to Health | 1 | 2015 | 434 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 487 | 0.090 |
Why?
| | Glucuronidase | 1 | 2011 | 25 | 0.090 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2011 | 24 | 0.080 |
Why?
| | Stroke | 1 | 2020 | 1254 | 0.080 |
Why?
| | Benzodiazepines | 2 | 2022 | 165 | 0.080 |
Why?
| | Chronic Disease | 1 | 2017 | 1812 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2917 | 0.080 |
Why?
| | Respiratory Mechanics | 1 | 1990 | 72 | 0.080 |
Why?
| | Goals | 2 | 2022 | 180 | 0.070 |
Why?
| | Prevalence | 1 | 2016 | 2815 | 0.070 |
Why?
| | Animals | 14 | 2011 | 38030 | 0.070 |
Why?
| | Mice, SCID | 2 | 2006 | 369 | 0.070 |
Why?
| | Receptors, Thrombin | 2 | 1998 | 15 | 0.070 |
Why?
| | Killer Cells, Natural | 3 | 2006 | 467 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 621 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1559 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 674 | 0.070 |
Why?
| | Nigeria | 1 | 2007 | 24 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 1990 | 383 | 0.070 |
Why?
| | Albumins | 3 | 2005 | 118 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2011 | 404 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2011 | 374 | 0.060 |
Why?
| | Adolescent | 3 | 2021 | 22281 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2009 | 366 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 259 | 0.060 |
Why?
| | Religion | 1 | 2007 | 65 | 0.060 |
Why?
| | Hospitals | 2 | 2022 | 727 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2020 | 11643 | 0.060 |
Why?
| | Mice | 8 | 2009 | 18329 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2006 | 5988 | 0.060 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2006 | 49 | 0.060 |
Why?
| | Mice, Inbred A | 1 | 2006 | 48 | 0.060 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 26 | 0.060 |
Why?
| | Hydroxydopamines | 1 | 2005 | 4 | 0.060 |
Why?
| | Toll-Like Receptor 9 | 1 | 2006 | 37 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1147 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 299 | 0.060 |
Why?
| | Social Workers | 1 | 2026 | 56 | 0.060 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 251 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 235 | 0.060 |
Why?
| | Vaccination | 1 | 2014 | 1422 | 0.060 |
Why?
| | Mental Status and Dementia Tests | 1 | 2025 | 26 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3637 | 0.060 |
Why?
| | Editorial Policies | 1 | 2026 | 46 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2026 | 311 | 0.060 |
Why?
| | Preoperative Period | 1 | 2025 | 148 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2006 | 205 | 0.050 |
Why?
| | Self Report | 2 | 2019 | 863 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3403 | 0.050 |
Why?
| | CD3 Complex | 1 | 2005 | 111 | 0.050 |
Why?
| | Publishing | 1 | 2026 | 114 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2006 | 919 | 0.050 |
Why?
| | Conscience | 1 | 2024 | 9 | 0.050 |
Why?
| | Postoperative Period | 1 | 2025 | 353 | 0.050 |
Why?
| | Lymphocyte Activation | 2 | 2006 | 1126 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2005 | 155 | 0.050 |
Why?
| | Cell Membrane Permeability | 2 | 1997 | 85 | 0.050 |
Why?
| | Rats | 3 | 2011 | 5592 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 85 | 0.050 |
Why?
| | Immunoconjugates | 1 | 2005 | 132 | 0.050 |
Why?
| | Terminally Ill | 1 | 2023 | 41 | 0.050 |
Why?
| | Specialization | 1 | 2024 | 134 | 0.050 |
Why?
| | Epidemics | 1 | 2024 | 98 | 0.050 |
Why?
| | Morals | 1 | 2023 | 80 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 824 | 0.050 |
Why?
| | Preoperative Care | 1 | 2025 | 379 | 0.050 |
Why?
| | Pregnancy Proteins | 1 | 2002 | 35 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 863 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 600 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2009 | 927 | 0.040 |
Why?
| | Patient Care | 1 | 2023 | 118 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2005 | 784 | 0.040 |
Why?
| | Cohort Studies | 1 | 2012 | 5935 | 0.040 |
Why?
| | Asia | 1 | 2021 | 70 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2025 | 365 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 169 | 0.040 |
Why?
| | Permeability | 2 | 2005 | 168 | 0.040 |
Why?
| | Neutrophils | 1 | 2006 | 1134 | 0.040 |
Why?
| | Senior Centers | 1 | 2019 | 1 | 0.040 |
Why?
| | Thrombectomy | 1 | 2020 | 77 | 0.040 |
Why?
| | Ownership | 1 | 2020 | 111 | 0.040 |
Why?
| | Leukocytes | 1 | 2001 | 295 | 0.040 |
Why?
| | Cell Line | 2 | 2011 | 2879 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 292 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 371 | 0.040 |
Why?
| | Incidence | 1 | 2025 | 2870 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 280 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 79 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2020 | 173 | 0.040 |
Why?
| | Protein Kinase C beta | 1 | 1998 | 21 | 0.040 |
Why?
| | RNA, Antisense | 1 | 1998 | 18 | 0.040 |
Why?
| | Safety | 1 | 2020 | 355 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1998 | 153 | 0.030 |
Why?
| | Minority Health | 1 | 2018 | 18 | 0.030 |
Why?
| | Professional-Patient Relations | 1 | 2019 | 153 | 0.030 |
Why?
| | Social Values | 1 | 2018 | 39 | 0.030 |
Why?
| | Time Factors | 4 | 2020 | 7155 | 0.030 |
Why?
| | Informed Consent | 1 | 2019 | 198 | 0.030 |
Why?
| | Feedback | 1 | 1998 | 181 | 0.030 |
Why?
| | Interdisciplinary Research | 1 | 2017 | 26 | 0.030 |
Why?
| | California | 1 | 2018 | 469 | 0.030 |
Why?
| | Skin | 2 | 1998 | 754 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 156 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 347 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1312 | 0.030 |
Why?
| | Students | 1 | 2021 | 661 | 0.030 |
Why?
| | Racism | 1 | 2018 | 151 | 0.030 |
Why?
| | Antibodies | 1 | 1997 | 401 | 0.030 |
Why?
| | Stimulation, Chemical | 1 | 1994 | 53 | 0.030 |
Why?
| | Second Messenger Systems | 1 | 1994 | 31 | 0.030 |
Why?
| | Personal Autonomy | 1 | 2015 | 57 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 940 | 0.020 |
Why?
| | Biological Transport | 1 | 1994 | 412 | 0.020 |
Why?
| | Pain | 1 | 2018 | 777 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2008 | 1172 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2011 | 2525 | 0.020 |
Why?
| | Spleen | 2 | 2004 | 508 | 0.020 |
Why?
| | Streptozocin | 1 | 2011 | 21 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1104 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 1990 | 46 | 0.020 |
Why?
| | Gerbillinae | 1 | 1990 | 72 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 198 | 0.020 |
Why?
| | Pressure | 1 | 1990 | 225 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 336 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1989 | 275 | 0.020 |
Why?
| | Child | 1 | 2007 | 22537 | 0.020 |
Why?
| | Apoptosis | 2 | 2006 | 2430 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2026 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1253 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1264 | 0.020 |
Why?
| | Horseradish Peroxidase | 1 | 2005 | 26 | 0.010 |
Why?
| | Cell Division | 2 | 2002 | 766 | 0.010 |
Why?
| | Integrin beta3 | 1 | 2005 | 14 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 71 | 0.010 |
Why?
| | Leukemia L5178 | 1 | 2005 | 1 | 0.010 |
Why?
| | Glucose | 1 | 2011 | 1046 | 0.010 |
Why?
| | CpG Islands | 1 | 2006 | 165 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2009 | 353 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2005 | 114 | 0.010 |
Why?
| | Substantia Nigra | 1 | 2005 | 63 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 251 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 320 | 0.010 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 928 | 0.010 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2004 | 26 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2006 | 322 | 0.010 |
Why?
| | Gangliosides | 1 | 2004 | 23 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2005 | 246 | 0.010 |
Why?
| | Functional Laterality | 1 | 2005 | 241 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 269 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2004 | 397 | 0.010 |
Why?
| | Ligands | 1 | 2005 | 673 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 283 | 0.010 |
Why?
| | Megakaryocytes | 1 | 2002 | 34 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2002 | 4146 | 0.010 |
Why?
| | CHO Cells | 1 | 2002 | 171 | 0.010 |
Why?
| | Cricetinae | 1 | 2002 | 303 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1092 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2004 | 688 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1715 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2002 | 320 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4556 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1367 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2002 | 420 | 0.010 |
Why?
| | Gestational Age | 1 | 2002 | 975 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 803 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2005 | 3119 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 114 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1997 | 181 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1997 | 136 | 0.010 |
Why?
| | Microcirculation | 1 | 1997 | 138 | 0.010 |
Why?
| | Serum Albumin | 1 | 1997 | 147 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 2048 | 0.010 |
Why?
| | Binding Sites | 1 | 1997 | 1327 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1997 | 698 | 0.010 |
Why?
| | Models, Molecular | 1 | 1997 | 1618 | 0.010 |
Why?
| | Pregnancy | 1 | 2002 | 7180 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1989 | 416 | 0.000 |
Why?
| | Actins | 1 | 1989 | 422 | 0.000 |
Why?
| | Cattle | 1 | 1989 | 999 | 0.000 |
Why?
| | Cell Survival | 1 | 1989 | 1098 | 0.000 |
Why?
| | Cell Membrane | 1 | 1989 | 706 | 0.000 |
Why?
|
|
Lum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|